Lenalidomide shortage — availability across Europe

Key facts

• As of 9 September 2026, Lenalidomide has active availability issues in 6 of 9 tracked European registers.
• Registers reporting issues: Austria, Spain, Greece, Ireland, Italy, Sweden.
• Latest expected-resolution date on file: 2027-04-29.
• Longest-running open report: since 2022-12-12 (45 months, Sweden).
• Data source: 7 official medicines-agency registers, refreshed daily.

As of 9 September 2026, 6 of the 9 tracked registers list current availability issues for Lenalidomide, covering 39 affected product presentations. The longest-running open report was filed in Sweden on 2022-12-12 and has now been open for about 45 months. Where agencies state a cause, manufacturing problems lead with 8 of the 21 stated-cause reports, followed by unexpectedly high demand with 7. The furthest expected-resolution date currently on file is 2027-04-29; the earliest is 2026-10-14. Notably, 2 reports have already passed the expected-resolution date without closing — prognoses for this medicine should be read as estimates, not commitments. Momentum is current, not historical: 14 of the open reports were filed within the last 90 days. The issue spread across registers over time rather than at once: Sweden reported first (2022-12-12), with Austria following roughly 41 months later — a pattern typical of supply problems cascading between national markets. Registers in Spain, Ireland, Italy, Sweden indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching. In the WHO ATC classification, Lenalidomide is coded L04AX04 — a medicine acting on antineoplastic and immunomodulating agents — so clinically related products appear under “Related medicines” below.

New register reports per month

Full report history (40 register entries)

Every individual register entry for Lenalidomide in the tracked sources, newest first — including resolved and discontinued reports.

Frequently asked

Is Lenalidomide currently in shortage in Europe?

Yes. As of 9 September 2026, availability issues are reported in: Austria, Spain, Greece, Ireland, Italy, Sweden. Availability is national — a shortage in one country does not mean it is short everywhere.

When is the Lenalidomide shortage expected to end?

Agency prognoses on file range from 2026-10-14 to 2027-04-29. These are manufacturer-reported estimates and frequently move; check the linked register entry for the latest date.

Are there alternatives to Lenalidomide?

36 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.

Where does this Lenalidomide availability data come from?

Directly from the official medicines-agency registers that list Lenalidomide: BASG (Austria), AEMPS CIMA (Spain), ANSM (France), EOF limited-availability list (Greece), HPRA (Ireland), AIFA (Italy), Läkemedelsverket (Sweden). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.

Related medicines (same ATC class)

Embed this tracker

Pharmacies, patient sites and newsrooms are welcome to embed the live status of Lenalidomide — free, with attribution. Copy this snippet:

<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/lenalidomide/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Lenalidomide availability in Europe"></iframe>
<p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/lenalidomide/">Lenalidomide shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>